Pharmacokinetics of the second generation of antidepressant drugs;Farmakokinetyka przeciwdepresyjnych leków drugiej generacji

Psychiatria Polska

Volumn 34, Issue 4, 2000, Pages 577-594

  Grzesiak, M ^a   Beszlej, J A ^a   Kiejna, A ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Antidepressant drugs; Pharmacokinetics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; DEBRISOQUINE; DESIPRAMINE; DIAZEPAM; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPARTEINE; TIANEPTINE; VENLAFAXINE;

DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME POLYMORPHISM; HUMAN; NONHUMAN; POLYPHARMACY; REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; HUMANS;

EID: 0034503616     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Clinical pharmacokinetics of fluoxetine
2. Paradoxe of tianeptine
3. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, digoxin
4. Trazodone and nefazodone
5. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors
6. The pharmacokinetics of citalopram
7. Pharmacogenetics of antidepressants: Clinical aspects
8. From dirty drugs to hyperselectivity and part way back again
9. Inhibition by paroxetine of desipramine metabolism in extensive but not pooor metabolisers of sparteine
10. Metabolism of newer antidepressants. An overview of the pharmacological and pharmacokinetic implications
11. The effect of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes
12. In vitro and in vivo studies on the disposition of mirtazapine in humans
13. Pharmacokinetics of paroxetine in patients with cirrhosis
14. Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly
15. Pharmacokinetics of the newer antidepressants: Clinical relevance
16. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine
17. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers
18. Pharmacokinetic optimisation of therapy with newer antidepressants
19. Citalopram: Interaction studies with levomepromazine, imipramine and lithium
20. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine
21. Clinical pharmacokinetics of nefazodone
22. Monoamine oxidase inhibitors
23. The pharmacology and mode action of venlafaxine
24. Serum fluoxetine and norfluoxetine concentrations and antidepressant response
25. Identification of cytochrom P450 isoforms involved in citalopram N-demetylation by human liver microsomes
26. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers
27. Milnacipran: The clinical properties of a selective serotonin and noradrenaline reuptake inhibitor (SNRI)
28. Drug interaction potential of fluoxetine, sertraline and paroxetine in four state psychiatric hospital populations
29. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities
30. Newer antidepressants and the cytochrome P450 system
31. Mirtazapine: Pharmacology in relation to adverse effects
32. Designing a new generation of antidepressant drug
33. Clinically relevant pharmacology of selective serotonin reuptake inhibitors
34. Interakcje selektywnych inhibitorów wychwytu serotoniny
35. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers
36. Sertraline. Chronopharmacikinetics and the effect of coadministration with food
37. Tianeptine and its main metabolite. Pharmacokinetics in chronic alkoholism and cirrhosis
38. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis
39. The tolerability of venlafaxine
40. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxydation polymorphism
41. Interaction between fluoxamine and imipramine/desipramine in four patients
42. Effect of fluoxamine on the pharmacokinetics of imipramine and dezsipramine in healthy subjects
43. Selective serotonin reuptake inhibitors and CNS drug interactions
44. Meta-analysis of randomised, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amityptyline in major depression
45. Interaction of enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
46. Zagadnienia farmakologiczne i toksykologiczne
47. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide
48. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
49. The influence of various drugs on the binding of tianeptine to human plasma proteins